Isabelle Ray-Coquard, MD, PhD, Léon Bérard Center, Lyon, France, discusses two international Phase III trials, IMagyn050/GOG 3015/ENGOT-OV39 (NCT03038100) and ICON8 (NCT00538603), which both evaluated ovarian cancer treatment in front-line setting. The IMagyn050/GOG 3015/ENGOT-OV39 study evaluated bevacizumab-containing therapy +/- atezolizumab and showed that atezolizumab did not significantly improve PFS in the intent-to-treat or PD-L1+ population. The ICON8 study investigated the safety and efficacy of weekly dose-dense vs three-weekly standard chemotherapy. This study concluded that although weekly dose-dense chemotherapy is a safer alternative, it does not significantly improve progression-free survival or overall survival. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
